Should I Buy ANL? ANL 2026 Analysis

Should You Buy Adlai Nortye Ltd (ANL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

10.010

1 Day change

-1.28%

52 Week Range

12.090

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Not a good buy right now (pre-market $10.03, +6.70%): price is extended/overbought and sitting just below a major resistance level, making the risk/reward poor for an impatient entry.
Best interpretation of the setup: bullish trend, but short-term overheated; odds favor a near-term pullback more than an immediate clean breakout.
If you must act immediately, this reads more like a chase-risk “hold/avoid new buys” rather than a high-quality entry.

Technical Analysis

Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200, confirming strong upward momentum.
Momentum: MACD histogram +0.865 and expanding → bullish momentum still building.
Overbought condition: RSI_6 = 81.59 → historically stretched; increases probability of a shakeout/pullback.
Key levels:
- Current pre-market: 10.03
- R1: 10.316 (nearby resistance; limited immediate upside before supply likely shows)
- R2: 12.749 (next upside zone if R1 breaks convincingly)
- Pivot: 6.377 (meaningful downside mean-reversion area if momentum fades)
Pattern-based forward look (provided): indicates higher near-term downside risk (60% chance of -4.12% next day) even though the medium-term read shows potential strength (as stated for next week/month).

Positive Catalysts

- $140M private placement financing (2026-02-03) improves liquidity/runway and can support continued oncology pipeline development.
- New bullish coverage: Lucid Capital initiated Buy with $11 PT, highlighting potential upside tied to de-risking of pan-RAS inhibitor AN9025.
- Current technical trend is clearly bullish (moving averages + MACD).

Neutral/Negative Catalysts

- Dilution/financing overhang: private placement involved selling ~64.6M shares at $2.1667, which is highly dilutive and can create future selling pressure depending on terms/lockups.
- Overbought + near resistance: RSI is extreme and price is just below R1 (10.316), increasing the chance of rejection/pullback.
- No Intellectia buy-timing support today (no AI Stock Picker and no SwingMax entry), weakening the “buy now” case.
- News list contains items not directly related to ANL (Xpeng, SanDisk), offering no additional stock-specific upside catalyst from those headlines.

Financial Performance

Financial data unavailable: “Financial snapshot: Error: list index out of range” (cannot assess latest quarter results, growth, or cash burn trends from the provided dataset).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: A new initiation on 2026-01-29 by Lucid Capital (Christopher Liu): Buy, $11 price target.
Wall Street pro view (pros): Focus on pipeline optionality and potential value inflection if AN9025 becomes de-risked.
Wall Street pro view (cons): Clinical-stage biotech risk plus recent large-share issuance can pressure sentiment/valuation despite bullish targets.
Influential/political trading: No recent congress trading data available; hedge funds and insiders flagged as Neutral with no significant recent trends.

Analyst Rating

Wall Street analysts forecast ANL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 10.140

Low

Averages

High

Current: 10.140

Low

Averages

High

Lucid Capital

Christopher Liu

Buy

initiated

$11

AI Analysis

2026-01-29

Reason

Lucid Capital

Christopher Liu

Price Target

$11

AI Analysis

2026-01-29

initiated

Buy

Reason

Lucid Capital analyst Christopher Liu initiated coverage of Adlai Nortye with a Buy rating and $11 price target. Adlai is a clinical-stage biotechnology company focused on developing novel oncology therapies, the analyst tells investors in a research note. The firm believes thee company's pan-RAS inhibitor, AN9025, could be a "significant potential value driver for shares as the asset becomes de-risked."

H.C. Wainwright

Buy -> Neutral

downgrade

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Adlai Nortye to Neutral from Buy.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANL

Unlock Now

ANL Should I Buy

ANL Should I Buy

Should You Buy Adlai Nortye Ltd (ANL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch